462 related articles for article (PubMed ID: 31398437)
1. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
[TBL] [Abstract][Full Text] [Related]
2. Storage stability of phage-ciprofloxacin combination powders against Pseudomonas aeruginosa respiratory infections.
Lin Y; Yoon Kyung Chang R; Britton WJ; Morales S; Kutter E; Li J; Chan HK
Int J Pharm; 2020 Dec; 591():119952. PubMed ID: 33059012
[TBL] [Abstract][Full Text] [Related]
3. Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.
Chang RYK; Chen K; Wang J; Wallin M; Britton W; Morales S; Kutter E; Li J; Chan HK
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158280
[TBL] [Abstract][Full Text] [Related]
4. Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection.
Chang RY; Wong J; Mathai A; Morales S; Kutter E; Britton W; Li J; Chan HK
Eur J Pharm Biopharm; 2017 Dec; 121():1-13. PubMed ID: 28890220
[TBL] [Abstract][Full Text] [Related]
5. Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa.
Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Chan HK
Int J Pharm; 2018 Nov; 551(1-2):158-165. PubMed ID: 30223075
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model.
Lin Y; Quan D; Chang RYK; Chow MYT; Wang Y; Li M; Morales S; Britton WJ; Kutter E; Li J; Chan HK
Eur J Pharm Biopharm; 2021 Jan; 158():166-171. PubMed ID: 33253892
[TBL] [Abstract][Full Text] [Related]
7. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
[TBL] [Abstract][Full Text] [Related]
8. Storage stability of inhalable phage powders containing lactose at ambient conditions.
Chang RYK; Wallin M; Kutter E; Morales S; Britton W; Li J; Chan HK
Int J Pharm; 2019 Apr; 560():11-18. PubMed ID: 30710661
[TBL] [Abstract][Full Text] [Related]
9. Phage cocktail powder for Pseudomonas aeruginosa respiratory infections.
Li M; Chang RYK; Lin Y; Morales S; Kutter E; Chan HK
Int J Pharm; 2021 Mar; 596():120200. PubMed ID: 33486032
[TBL] [Abstract][Full Text] [Related]
10. Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.
Shetty N; Park H; Zemlyanov D; Mangal S; Bhujbal S; Zhou QT
Int J Pharm; 2018 Jun; 544(1):222-234. PubMed ID: 29678544
[TBL] [Abstract][Full Text] [Related]
11. Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections.
Yu S; Wang S; Zou P; Chai G; Lin YW; Velkov T; Li J; Pan W; Zhou QT
Int J Pharm; 2020 Feb; 575():118915. PubMed ID: 31816354
[TBL] [Abstract][Full Text] [Related]
12. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
Adi H; Young PM; Chan HK; Agus H; Traini D
Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
[TBL] [Abstract][Full Text] [Related]
13. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
Yu H; Teo J; Chew JW; Hadinoto K
Int J Pharm; 2016 Feb; 499(1-2):38-46. PubMed ID: 26757148
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
Karimi K; Katona G; Csóka I; Ambrus R
J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
[TBL] [Abstract][Full Text] [Related]
15. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
Yu J; Chan HK; Gengenbach T; Denman JA
Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
[TBL] [Abstract][Full Text] [Related]
16. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
[TBL] [Abstract][Full Text] [Related]
17. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
Zhou QT; Sun SP; Chan JG; Wang P; Barraud N; Rice SA; Wang J; Li J; Chan HK
Mol Pharm; 2015 Aug; 12(8):2594-603. PubMed ID: 25423590
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis.
Alhajj N; Yahya MFZR; O'Reilly NJ; Cathcart H
Eur J Pharm Sci; 2024 Jan; 192():106654. PubMed ID: 38013123
[TBL] [Abstract][Full Text] [Related]
19. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
Wang J; Kutter JP; Mu H; Moodley A; Yang M
Int J Pharm; 2020 Nov; 590():119877. PubMed ID: 32927003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
